Roy Sanchari, Trautwein Christian, Luedde Tom, Roderburg Christoph
Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Front Pharmacol. 2018 Aug 15;9:805. doi: 10.3389/fphar.2018.00805. eCollection 2018.
Liver diseases contribute to the global mortality and morbidity and still represent a major health problem leading to the death of people worldwide. Although there are several treatment options available for Hepatitis C infections, for most liver disease the pharmacological options are still limited. Therefore, the development of new targets against liver diseases is of high interest. Non-coding RNA (ncRNA) such as microRNA (miRNA) or long ncRNA (lncRNA) have been shown to be deeply involved in the pathophysiology of almost all acute and chronic liver diseases. The emerging evidence showed the potential therapeutic use of miRNA associated with different steps of hepatic pathophysiology. In the present review, we summarize emerging insights of ncRNA in liver diseases. We also highlight example of ncRNAs participating in the pathogenesis of different forms of liver disease and how they can be used as potential therapeutic targets for novel treatment paradigms. Furthermore, we describe an overview of up-to-date clinical trials and discuss about its future in clinical applications. Finally, we highlight the role of circulating ncRNAs in diagnosis of liver diseases and discuss the challenges and drawbacks of the usage of ncRNAs in clinical setting.
肝脏疾病导致全球范围内的死亡和发病,仍然是导致世界各地人们死亡的主要健康问题。尽管丙型肝炎感染有多种治疗选择,但对于大多数肝脏疾病来说,药物治疗选择仍然有限。因此,开发针对肝脏疾病的新靶点备受关注。非编码RNA(ncRNA),如微小RNA(miRNA)或长链非编码RNA(lncRNA),已被证明深度参与几乎所有急性和慢性肝脏疾病的病理生理学过程。新出现的证据表明,与肝脏病理生理学不同阶段相关的miRNA具有潜在的治疗用途。在本综述中,我们总结了ncRNA在肝脏疾病方面的新见解。我们还重点介绍了参与不同形式肝脏疾病发病机制的ncRNA实例,以及它们如何用作新型治疗模式的潜在治疗靶点。此外,我们概述了最新的临床试验,并讨论了其在临床应用中的未来。最后,我们强调了循环ncRNA在肝脏疾病诊断中的作用,并讨论了在临床环境中使用ncRNA的挑战和缺点。